Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ira M Turner

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Headache|February 12, 2005
Migraine, botulinum toxin type-A, and the disappearing sebaceous cystIra M Turner, Tiffany Agrillo
Headache|June 19, 2013
A cross-sectional survey to assess the migraineur's medication decision-making beliefs: determining when a migraine is triptan-worthyStephen H Landy, Ira M Turner, M Chris Runken, et al.
Journal of Primary Care & Community Health|September 28, 2020
Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic MigraineAndrew M Blumenfeld, Atul T Patel, Ira M Turner, et al.
BMC Neurology|August 15, 2019
Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)Li Shen Loo, Brian M Plato, Ira M Turner, et al.
Headache|May 20, 2011
Multi-center comparison of response to a single tablet of sumatriptan 85 mg and naproxen 500 mg vs usual therapy treating multiple migraine attacks as measured by the completeness of response surveyRoger Cady, Jim Banks, Robert B Nett, et al.
Journal of the Neurological Sciences|June 25, 2013
OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baselineStephen D Silberstein, Andrew M Blumenfeld, Roger K Cady, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Headache|February 12, 2005
Migraine, botulinum toxin type-A, and the disappearing sebaceous cystIra M Turner, Tiffany Agrillo
Headache|June 19, 2013
A cross-sectional survey to assess the migraineur's medication decision-making beliefs: determining when a migraine is triptan-worthyStephen H Landy, Ira M Turner, M Chris Runken, et al.
Journal of Primary Care & Community Health|September 28, 2020
Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic MigraineAndrew M Blumenfeld, Atul T Patel, Ira M Turner, et al.
BMC Neurology|August 15, 2019
Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)Li Shen Loo, Brian M Plato, Ira M Turner, et al.
Headache|May 20, 2011
Multi-center comparison of response to a single tablet of sumatriptan 85 mg and naproxen 500 mg vs usual therapy treating multiple migraine attacks as measured by the completeness of response surveyRoger Cady, Jim Banks, Robert B Nett, et al.
Journal of the Neurological Sciences|June 25, 2013
OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baselineStephen D Silberstein, Andrew M Blumenfeld, Roger K Cady, et al.
Pageof 1